Rodney Felgate, MD
Family Medicine · Lincoln, NHNPI 1801980453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $657, 5.3 times the $124 reported in 2019. Among family medicine clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$460
- Novo Nordisk$312
- GSK$300
- Pfizer$163
- AbbVie$127
- Covidien LP$92
- plus $728 from 22 others
What the payments were for
- Food & beverage$2,13298%
- Education$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $460 |
| Novo Nordisk | 16 | $312 |
| GSK | 28 | $300 |
| Pfizer | 9 | $163 |
| AbbVie | 7 | $127 |
| Covidien LP | 1 | $92 |
| Merck | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Astellas Pharma US Inc | 2 | $65 |
| Amgen | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| Boehringer Ingelheim | 3 | $47 |
| Johnson & Johnson | 2 | $41 |
| Indivior Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Collegium Pharmaceutical, Inc. | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 2 | $24 |
| Echosens North America, Inc. | 2 | $23 |
| Exact Sciences | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Novartis | 1 | $18 |
| Abbott | 1 | $17 |
| Eisai Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$2,182 in reported general payments places this provider in the 90th percentile of 397 family medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 48 | $58,947 |
| OtezlaApremilast | 11 | $52,428 |
| XareltoRivaroxaban | 25 | $39,373 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $29,809 |
| OzempicSemaglutide | 17 | $22,749 |
| QuliptaAtogepant | 13 | $16,533 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $11,409 |
| Levemir FlexpenInsulin Detemir | 19 | $5,792 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,132 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 41 | $2,841 |
| Atorvastatin Calcium | 207 | $2,383 |
| RitalinMethylphenidate Hcl | 14 | $1,738 |
| Metoprolol Succinate | 126 | $1,649 |
| Lisdexamfetamine Dimesylate | 14 | $1,581 |
| Esomeprazole Magnesium | 21 | $1,566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $163 | $58,94748 claims |
| AmgenOtezla | $53 | $52,42811 claims |
| Johnson & JohnsonXarelto | $41 | $39,37325 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $300 | $34,94045 claims |
| Novo NordiskOzempic | $312 | $22,74917 claims |
| AbbVieQulipta | $127 | $16,53313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 397 family medicine providers in New Hampshire.
Other family medicine in Lincoln
- Mark BallentynePortsmouth$135K
- M LauterPortsmouth$21K
- Brian SponsellerNorth Conway$15K
- Cecilia Vicuna KeadyCharlestown$13K
- Keenan Al-HojerryPortsmouth$11K
- Peter LoeserConcord$10K
- Robyn StewartDerry$8K
- Robert KellyExeter$8K
- Dennis BadmanSanbornville$7K
- Ajay KoshyBedford$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.